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Clostridium difficile Infection:
Difficult to Control?
Clostridium difficile can cause large-scale
outbreaks of diarrhea [1,2]. Significant
progress has recently been achieved to
improve treatment of symptomatic C.
difficile disease [3]. But hospitals affected
by C. difficile infection still face challenges
in the effort to control endemic C. difficile
infections, which may be related to
overuse of antibiotics (e.g., fluoroquino-
lones, cephalosporins), problems in clean-
ing services, and poor isolation practices
[4,5]. Furthermore, current diagnostic
tests for C. difficile are not sensitive enough
[6] and diagnosis can be delayed [7].
Evidence for the rate of nosocomial
acquisition of C. difficile and the likelihood
of within-hospital transmission from pa-
tients to patients of C. difficile infection
remains scarce, so an improved evidence
base could help improve infection control
strategies [8]. Only a few studies have
examined in detail the prevalence of C.
difficile in hospital patients upon admission
and nosocomial transmission rates of C.
difficile infection [9]. For instance, 15 years
ago, Samore et al. reported that for most
epidemiologically linked contacts of C.
difficile cases, positive cultures for C. difficile
did not result from transmission from the
presumed index case [8]. However, this
and other studies were conducted before
the emergence of new hypervirulent C.
difficile strains and might not reflect the




In a new study published in this issue of
PLoS Medicine, Sarah Walker and col-
leagues examine the epidemiology of C.
difficile infection, focusing on the role of
within-hospital transmission among ward
patients. The investigators used a simpli-
fied model that was populated with
observational data from one National
Health Service (NHS) Hospital Trust in
the United Kingdom, a country that
introduced compulsory surveillance with
mandatory C. difficile testing of all elderly
inpatients with diarrhea in 2008 [10].
Surprisingly, based on the results of their
network analysis combined with molecular
strain typing, up to three-quarters of
patients with C. difficile infection did not
acquire their infecting C. difficile strain
during their hospital stay. Using time
intervals, strain types, and patient location
as plausibility checks, the authors propose
that within-hospital transmission account-
ed for a relatively small number of the
overall C. difficile cases detected. However,
the rates of transmission varied in different
specialty wards, with renal and transplant
wards having the highest documented
rates. Most of the cases of C. difficile that
were attributed to within-hospital trans-
mission occurred shortly after the onset of
symptoms of the index case, suggesting
that the hospital environment was not, as
has previously been claimed, a long-lasting
reservoir for this pathogen [7]. Overall,
this study suggests that alternative expla-
nations need to be sought for the origin of
most of the new onset cases of C. difficile
infection.
Moving On—What Do We Need
to Know Next about C. difficile
Transmission?
This impressive study addresses an
important question—to what extent can
we control C. difficile infection by preven-
tion of transmission from symptomatic C.
difficile infection cases in hospitals? How-
ever, there are limitations to the approach
chosen in this study, including several
possible sources of bias already mentioned
by the authors (e.g., selection, misclassifi-
cation, and information biases).
Other potential limitations not consid-
ered in this study include the possibility of
inter-ward transmission. Patients from
different wards might, for instance, be
transported to common sectors of the
hospital for procedures and diagnostic
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Linked Research Article
This Perspective discusses the
following new study published in
PLoS Medicine:
Walker AS, Eyre DW, Wyllie DH,
Dingle KE, Harding RM, et al.
(2012) Characterisation of Clostridi-
um difficile Hospital Ward–Based
Transmission Using Extensive Epi-
demiological Data and Molecular
Typing. PLoS Med 9(2): e1001172.
doi:10.1371/journal.pmed.1001172
A population-based study in Oxford-
shire (UK) hospitals by Sarah Walker
and colleagues finds that in an
endemic setting with good infection
control, ward-based contact cannot
account for most new cases of
Clostridium difficile infection.
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transmission, including equipment and
health care workers who might care for
patients on different wards, could be
similarly mobile. In this study, wards were
small relative to the hospital size. It is likely
that, on average, many more symptomatic
C. difficile cases were housed on ‘‘other’’
wards than on the ‘‘same’’ ward. Even
though rates of intra-ward transmission per
infected case were probably significantly
higher than rates of inter-ward transmission
per infected case, the absolute number of
inter-ward transmissions may have, in fact,
exceeded the number of intra-ward trans-
missions. Second, the poor sensitivity of
the Enzyme Immuno-Assay (EIA) testing
method for C. difficile diagnosis may have
ignored a potentially significant pool of
undiagnosed C. difficile patients (which
could have been selected as controls,
introducing misclassification bias). Third,
antibiotic exposure data were not record-
ed, which could have biased the dates of
onset of symptoms and cross-transmission.
Finally, transmission events linked to
asymptomatic carriers were not routinely
detected [11].
Practical Implications
The two key practical questions related
to this study are 1) how much benefit is
accrued by blocking transmission from
symptomatic C. difficile infection cases; 2)
what proportion of the C. difficile infections
that are attributed to within-hospital
transmission instead represent already-
infected individuals who come into the
hospital carrying toxigenic C. difficile
strains in their gut flora. The study by
Sarah Walker and colleagues cannot
provide definitive answers to these ques-
tions because it has significant limitations
with respect to both issues. The study
cannot answer question 1, about benefit
accrued by blocking C. difficile transmis-
sion, because it did not examine inter-
ward transmission. Further, it cannot tell
us how many patients came in already
colonized or infected because it did not
examine asymptomatic C. difficile carriage
upon admission and discharge. Attempt-
ing to interpret the results of this study
with respect to these practical issues
highlights the need to utilise models that
account for the non-linear dynamics of
spread of C. difficile.
Future Studies
Further studies are needed to elucidate
answers to the two key questions we have
identified above. Investigations should
examine the possibility of transmission
from falsely EIA-negative symptomatic
patients, asymptomatic carriers (patients
or health care workers), and community
acquisition with importation of C. difficile
into the hospital setting [12], and this
might require both more data and the use
of more advanced transmission models
such as hidden Markov models.
More detailed screening data, such as a
study that reported screening of asymp-
tomatic C. difficile carriers in a large
prospective cohort [13], and new models
will help to answer the question of whether
C. difficile is less of an institutional and
more of a community problem than has
previously been thought. Proving that the
majority of nosocomial C. difficile infections
are actually imported into hospitals (with
toxigenic C. difficile strains being already
present on admission) would be ‘‘revolution-
ary’’—however, we believe that the evi-
dence generated by this study, albeit
tantalizing, is not yet sufficient to prove
this hypothesis.
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